Literature DB >> 18421166

Complex of human neutrophil elastase with 1/2SLPI.

Masahiro Koizumi1, Aiko Fujino, Kay Fukushima, Takashi Kamimura, Midori Takimoto-Kamimura.   

Abstract

SLPI (secretory leukocyte protease inhibitor) is a 107-residue non-glycosylated protease inhibitor, which inhibits a wide range of serine proteases, trypsin, chymotrypsin, neutrophil elastase, chymase and cathepsin G. X-ray crystallographic analyses have shown that SLPI comprises two separate domains of similar architecture [Grütter, Fendrich, Huber & Bode (1988), EMBO J. 7, 345-351] and the C-terminal domain interacts with bovine alpha-chymotrypsin. In order to understand SLPI's multiple functions against various serine proteases, the complex HNE (human neutrophil elastase) has been co-crystallized with 1/2SLPI (recombinant C-terminal domain of SLPI; Arg58-Ala107), which has a biological activity similar to full SLPI. The 1/2SLPI and HNE complex structure was solved at 1.7 A resolution, and compared with the interaction mechanism of elafin, which is a specific inhibitor of elastase. It was found that P1 Leu72i and six hydrogen bonds between the main chains in the primary contact region have sufficient ability to inhibit HNE and PPE (porcine pancreatic elastase), and P5 Tyr68i is important in increasing the selectivity of 1/2SLPI against HNE. The mechanisms of the functions of SLPI are relatively unknown, but the current study could help understand the selectivity of SLPI against HNE and PPE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421166      PMCID: PMC2394824          DOI: 10.1107/S0909049507060670

Source DB:  PubMed          Journal:  J Synchrotron Radiat        ISSN: 0909-0495            Impact factor:   2.616


Introduction

The SLPI (secretory leukocyte protease inhibitor) similar domain motif is present in several other secreted proteins called the WAP four-disulfide core (WFDC) domain family. Elafin is one of these proteins (Wiedow et al., 1990 ▶, 1991 ▶; Zani et al., 2004 ▶), a 57-residue protease inhibitor that is a potent and specific strong inhibitor of PPE and HLE (human leukocyte elastase). However, the SLPI C-terminal domain inhibits HNE but inhibits PPE weakly (Masuda et al., 1994 ▶). The X-ray structure shows that elafin inhibits PPE in a similar way as the SLPI C-terminal domain (Tsunemi et al., 1996 ▶). How are these differences in selectivity against serine proteases between SLPI and elafin caused? Elafin and SLPI have multiple important roles both in normal homeostasis and at the site of inflammation. These include anti-protease and anti-microbial activity as well as modulation of the response to LPS stimulation. Both are members of larger families of proteins secreted predominantly at mucosal sites and are modulated under multiple pathological conditions, and control the conditioning of the innate immune system. The functions of SLPIs are still unclear (Williams et al., 2006 ▶). We report here the details of their interactions with 1/2SLPI and HNE and describe the comparison with elafin:PPE complexes (Tsunemi et al., 1996 ▶).

Materials and methods

Crystallization

1/2SLPI was designed as a half-size SLPI, which corresponds to the C-terminal domain and is expressed in E. coli. HNE was purchased from Elastin Products Company (Pacific, MO, USA). To obtain the HNE and 1/2SLPI complex, the mixed sample was dialyzed against 20 mM Na-acetate buffer (pH 5.0) using Slide-A-Lyzer (5000 Mw) to remove excess 1/2SLPI molecules. The crystallization was performed using the sitting-drop vapor-diffusion method at 293 K. Jena Bioscience Screening kits were used for the initial condition search. The crystals appeared from 2.0 M Na-formate at pH 4.5 in a few days and grew to a typical crystal size of 0.4 × 0.2 × 0.01 mm in one week.

Data collection and processing

Data collection was carried out under nitrogen stream at 100 K using Quantum315 at beamline BL41XU of SPring-8. Paraton was chosen as a cryoprotectant and added to the crystallization condition 40%(v/v). The crystal belongs to P42212 with unit-cell constants of a = b = 106.64 Å, c = 55.12 Å. The data set was processed using Crystal Clear 1.3.5. The initial phase was determined by molecular replacement with only HNE using MOLREP (CCP4.6.01 suite).

Refinements

Refinements were carried out using REFMAC5 (CCP4.6.01 suite). After several cycles of map fitting of the HNE protein structure, we identified the electron density corresponding to 1/2SLPI. The 1/2SLPI model was constructed using QUANTA2000 (MSI) with reference to the elafin (Tsunemi et al., 1996 ▶) main-chain trace. The crystallographic data are shown in Table 1 ▶.
Table 1

Crystallographic data and refinement statistics of the HNE with 1/2SLPI complex

Values in parentheses are for the outer shell (1.741.70).

Data collection
Space group P42212
Cell dimensions () a = b = 106.64, c = 55.12
Resolution ()38.321.70 (1.741.70)
Total observations419005
No. of unique reflections35374
Redundancy11.84 (11.96)
Completeness (%)99.5 (99.6)
I/(I)18.5 (7.9)
R merge (%)6.4 (27.2)
 
Ramachandran plot
Core angles (%)89.6
Additional allowed angles (%)9.5
Generous allowed angles (%)0.9
Disallowed angles (%)0
 
Refinement statistics
Completeness for range (%)99.45
Reflections used for refinement33575
Reflections used for R free calculations1770 (5%)
Crystallographic R (%)20.3
R free (%)23.1
No. of protein atoms/average B-factor (2)1636/18.7
No. of inhibitor atoms/average B-factor (2)374/24.5
No. of sugar atoms/average B-factor (2)48/25.9
 
RMS deviations from ideal geometry
Bond distances ()0.011
Bond angles ()1.268

Results and discussions

Crystal structure of HNE and 1/2SLPI complex

Fig. 1(a) ▶ shows the complex structure of HNE and 1/2SLPI. In the contact region there are no covalent bonds between HNE and 1/2SLPI. The main-chain trace of HNE shows no differences from PDB (Protein Data Bank) id 1B0F (Cregge et al., 1998 ▶). 1/2SLPI consists of four anti-parallel strands (strand from A to D) and four disulfide bridges (Cys64iCys93i, Cys71iCys97i, Cys80iCys92i, Cys86iCys101i), which keep the shape of 1/2SLPI like a rigid wedge. There are a small number of intra-hydrogen bonds and electrostatic interactions in the 1/2SLPI structure (Fig. 1b ▶).
Figure 1

(a) The structure of the HNE and 1/2SLPI complex. The Cα linkage of 1/2SLPI is shown in blue and the Cα linkage of HNE is in yellow. (b) Schematic representation of the polypeptide chain folding of 1/2SLPI with its disulfide connectivities. Disulfide bonds are indicated by thin lines. The blue arrows show the twisted β-sheet (strands C, D), and the blue rectangles show the strands (strand A, B). AB and CD loops are shown by pink lines. Intramolecular hydrogen bonds are indicated by dashed lines, with distances shown. Intramolecular van der Waals interactions are also indicated at the bottom of the figure.

In these four strands, only two internal strands form a double-stranded twisted β-sheet (Lys91iGly95i and Gly98iVal102i) connected by five main-chain–main-chain hydrogen bonds. These two strands are joined by a β-hairpin loop at Met96iCys97i. No main-chain–main-chain hydrogen bond is formed between the two parallel strands A and C, and one hydrogen bond is formed between strands B and D. In the region between the long loop AB and the adjacent hairpin loop CD, only one hydrogen bond is formed, connecting N of Cys71i and O of Met96i. 1/2SLPI has almost the same structure as the C-terminal domain of the full SLPI structure (W. Bode, private communication), with the root-mean-square deviation (RMSD) of the backbone atoms being 1.04 Å for residues Arg58iAla107i. The AB loop (between strands A and B) of 1/2SLPI binding to the active site of HNE has no serious affect on the enzyme structure. Both 1/2SLPI and elafin have four disulfide bridges at the same positions. The sequence identity is 42%; however, the P1-residue of elafin is Ala24i. The main-chain structures of the AB loop of both 1/2SLPI and elafin are similar. The AB loop of elafin should have a large flexibility, like 1/2SLPI (unpublished NMR data). The primary interaction appears to be the P1-residue Leu72i, located in the S1 pocket, and the carbonyl oxygen accommodated in the oxyanion hole. 1/2SLPI:HNE has almost similar hydrogen bonds at P2′–P3 in the primary contact site as elafin:PPE. Another hydrogen bond, Tyr68i(OH)⋯Arg217A(N∊1), in the primary contact region is added (Fig. 2a ▶). Met96i (CD loop) is located near Phe215 with a longer distance than the usual van der Waals contact in the secondary contact region.
Figure 2

Schematic representation of the hydrogen-bonding interactions between the contact regions of (a) HNE and 1/2SLPI and (b) PPE and elafin (Tsunemi et al., 1996 ▶). Inhibitor residues are designated by ‘i’ after the sequence number. Intermolecular hydrogen bonds are indicated by dashed lines.

On the other hand, elafin has additional hydrogen bonds between the carbonyl oxygen of Leu20i (P5) and the main-chain NH of Arg217A in the primary contact region, and between the hydroxyl group of Ser48i and the carbonyl oxygen of Asp97 shown in Fig. 2(b) ▶ (Tsunemi et al., 1996 ▶). The RMSD of the backbone atoms between 1/2SLPI and elafin is 1.01 Å, calculated by superposing residues Arg59i–Val105i of 1/2SLPI onto Thr11iGln57i of elafin. As shown in Table 2 ▶, 1/2SLPI shows a wide range of inhibitory activity against some serine proteases. On the other hand, elafin is a potent and specific protein inhibitor of PPE and HNE.
Table 2

Inhibition constant (K i values) of elafin (Zani et al., 2004 ▶) and 50% inhibitory concentrations (IC50) of 1/2SLPI and against some serine proteases (Masuda et al., 1994 ▶)

  K i (M) of elafinIC50 of 1/2SLPI
 57 amino acids A1G5749 amino acids R58A107
 42% identity with 1/2SLPIC-terminal domain of SLPI
H. neutrophil elastase1 1010 1.3 108
P. pancreatic elastase1 109 3.3 105
H. cathepsin G 8.0 109
B. pancreatic chymotrypsin 8.0 109
B. pancreas trypsin 2.0 106

Difference in the inhibitory mechanism for elastases between elafin and 1/2SLPI

1/2SLPI:HNE has a similar interaction mode at P2′–P3 in the primary contact region as elafin:PPE. Figs. 3(a) and 3(b) ▶ show the S1 pocket of 1/2SLPI:HNE and elafin:PPE, respectively. They show that elafin does not fill the S1 pocket in the elafin:PPE complex structure and that SLPI fills the S1 pocket of HNE better. Leu72i (P1) of 1/2SLPI provides a large contribution in the recognition with HNE and PPE (Eisenberg et al., 1990 ▶). Fig. 3(c) ▶ shows PPE superposing onto 1/2SLPI:HNE; the S1 pocket of PPE is similar to those of HNE. 1/2SLPI should show the same inhibitory activity against PPE on the S1 pocket, but 1/2SLPI inhibits HNE more than PPE (Table 2 ▶).
Figure 3

Electrostatic surface representations of (a) the HNE complex with 1/2SLPI (ball and stick model), and (b) the PPE:elafin complex around the S1 pocket. Superposed representations of the PPE molecule onto HNE of the X-ray structure HNE:1/2SLPI. The solid surface shows HNE and the meshed surface shows PPE. Comparison of HNE and PPE (purple mesh) around (c) the S1 pocket and (d) the S5 pocket. (e) The sequence alignment between HNE and PPE around the S5 pocket. The conflict residues of PPE with Y68i are shown in the purple square.

To understand 1/2SLPI’s selectivity for HNE, we compared the interface of HNE and PPE around P5 and found a remarkable difference in these structures (Fig. 3 ▶). In the PPE’s binding interfaces, Tyr68i (P5) conflicts with a region (Ser169Val176) of PPE (shown in Figs. 3d and 3e ▶). Tyr68i may be flipping away to avoid the conflict and cannot interact with PPE. In the 1/2SLPI:HNE complex, 1/2SLPI requires at least six hydrogen bonds between the main chains at P2′–P3 for the inhibitory activity owing to Leu72i (P1) occupation in the S1 pocket. Then the additional interactions at Tyr68i (P5) are used to increase the inhibitory activity of 1/2SLPI against HNE, but the interaction of the second contact region is not so critical. On the other hand, elafin needs a full set of hydrogen-bonding interactions (seven hydrogen bonds of the main chain in the primary contact region and one in the secondary contact region) which should be essential for the inhibitory activity because Ala24i (P1) is insufficient in occupying the S1 site. The interacting mode of elafin:PPE may be kept in the elafin:HNE complex structure. It seems that the P1 and P5 residues of 1/2SLPI are important residues causing the selectivity against HNE.

Conclusion

The current study shows the interaction mode between 1/2SLPI and HNE and it is similar to the elafin:PPE interaction modes. Although elafin inhibits both HNE and PPE equally, 1/2SLPI prefers HNE to PPE. We found that there were two important structural mechanisms which explained the selectivity of 1/2SLPI. First, the sufficient inhibitory activity of 1/2SLPI consists of six hydrogen bonds between the main chains at P2′–P3, owing to P1 (Leu72i) occupation of the S1 pocket. Second, additional interaction at P5 (Tyr68i) is possible in HNE, but impossible in PPE. P1 and P5 are critical residues for the selectivity of 1/2SLPI against HNE. These recognition mechanisms for HNE may provide important information for understanding the multiple function of 1/2SLPI. To understand the versatility of 1/2SLPI against other serine proteases (chymotrypsin, trypsin, cathepsin etc.), we need additional structural information involving the structure determination of some other serine protease complexes with 1/2SLPI. The crystal structure coordinates have been deposited with the Protein Data Bank (code 2Z7F).
  9 in total

1.  Location of the protease-inhibitory region of secretory leukocyte protease inhibitor.

Authors:  S P Eisenberg; K K Hale; P Heimdal; R C Thompson
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

2.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence.

Authors:  O Wiedow; J M Schröder; H Gregory; J A Young; E Christophers
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

Review 3.  SLPI and elafin: one glove, many fingers.

Authors:  Steven E Williams; Thomas I Brown; Ali Roghanian; Jean-Michel Sallenave
Journal:  Clin Sci (Lond)       Date:  2006-01       Impact factor: 6.124

4.  Specific cleavage of secretory leukoprotease inhibitor by neutrophil elastase and saliva.

Authors:  K Masuda; T Suga; A Takeuchi; M Kanesaki; A Imaizumi; Y Suzuki
Journal:  Biochem Pharmacol       Date:  1994-08-17       Impact factor: 5.858

5.  Elafin is a potent inhibitor of proteinase 3.

Authors:  O Wiedow; J Lüademann; B Utecht
Journal:  Biochem Biophys Res Commun       Date:  1991-01-15       Impact factor: 3.575

6.  Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris.

Authors:  Marie-Louise Zani; Shila M Nobar; Sandrine A Lacour; Soazig Lemoine; Christian Boudier; Joseph G Bieth; Thierry Moreau
Journal:  Eur J Biochem       Date:  2004-06

7.  Inhibition of human neutrophil elastase. 4. Design, synthesis, X-ray crystallographic analysis, and structure-activity relationships for a series of P2-modified, orally active peptidyl pentafluoroethyl ketones.

Authors:  R J Cregge; S L Durham; R A Farr; S L Gallion; C M Hare; R V Hoffman; M J Janusz; H O Kim; J R Koehl; S Mehdi; W A Metz; N P Peet; J T Pelton; H A Schreuder; S Sunder; C Tardif
Journal:  J Med Chem       Date:  1998-07-02       Impact factor: 7.446

8.  Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.

Authors:  M Tsunemi; Y Matsuura; S Sakakibara; Y Katsube
Journal:  Biochemistry       Date:  1996-09-10       Impact factor: 3.162

9.  The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin.

Authors:  M G Grütter; G Fendrich; R Huber; W Bode
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

  9 in total
  14 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Three-dimensional Structure of a Kunitz-type Inhibitor in Complex with an Elastase-like Enzyme.

Authors:  Rossana García-Fernández; Markus Perbandt; Dirk Rehders; Patrick Ziegelmüller; Nicolas Piganeau; Ulrich Hahn; Christian Betzel; María de Los Ángeles Chávez; Lars Redecke
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

3.  Crystal structure of the Haemophilus influenzae Hap adhesin reveals an intercellular oligomerization mechanism for bacterial aggregation.

Authors:  Guoyu Meng; Nicole Spahich; Roma Kenjale; Gabriel Waksman; Joseph W St Geme
Journal:  EMBO J       Date:  2011-08-12       Impact factor: 11.598

4.  Determination of the X-ray structure of the snake venom protein omwaprin by total chemical synthesis and racemic protein crystallography.

Authors:  James R Banigan; Kalyaneswar Mandal; Michael R Sawaya; Vilasak Thammavongsa; Antoni P A Hendrickx; Olaf Schneewind; Todd O Yeates; Stephen B H Kent
Journal:  Protein Sci       Date:  2010-10       Impact factor: 6.725

5.  Staphylococcus aureus secretes a unique class of neutrophil serine protease inhibitors.

Authors:  Daphne A C Stapels; Kasra X Ramyar; Markus Bischoff; Maren von Köckritz-Blickwede; Fin J Milder; Maartje Ruyken; Janina Eisenbeis; William J McWhorter; Mathias Herrmann; Kok P M van Kessel; Brian V Geisbrecht; Suzan H M Rooijakkers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-26       Impact factor: 11.205

6.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

7.  X-ray structure analysis and characterization of AFUEI, an elastase inhibitor from Aspergillus fumigatus.

Authors:  Mayuko Sakuma; Katsumi Imada; Yoshiyuki Okumura; Kei-ichi Uchiya; Nobuo Yamashita; Kenji Ogawa; Atsushi Hijikata; Tsuyoshi Shirai; Michio Homma; Toshiaki Nikai
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

8.  Mechanism of heparin acceleration of tissue inhibitor of metalloproteases-1 (TIMP-1) degradation by the human neutrophil elastase.

Authors:  Gabriel L C Nunes; Alyne Simões; Fábio H Dyszy; Claudio S Shida; Maria A Juliano; Luiz Juliano; Tarsis F Gesteira; Helena B Nader; Gillian Murphy; Alain F Chaffotte; Michel E Goldberg; Ivarne L S Tersariol; Paulo C Almeida
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

9.  Structure basis 1/2SLPI and porcine pancreas trypsin interaction.

Authors:  Kei Fukushima; Takashi Kamimura; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-29       Impact factor: 2.616

Review 10.  Interactions in bacterial biofilm development: a structural perspective.

Authors:  James A Garnett; Steve Matthews
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.